Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 15 versus METHYLPHENIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 15 versus METHYLPHENIDATE.
ADDERALL XR 15 vs METHYLPHENIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
Methylphenidate is a central nervous system (CNS) stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their extracellular concentrations. It also acts as a dopamine and norepinephrine releaser. The therapeutic effect in ADHD is thought to be due to increased dopaminergic signaling in the prefrontal cortex.
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
Oral: Initial 5 mg twice daily (before breakfast and lunch), increase by 5-10 mg weekly; usual dose 20-30 mg/day in divided doses; maximum 60 mg/day. Extended-release: 18-36 mg once daily; maximum 72 mg/day.
None Documented
None Documented
Clinical Note
moderateDexmethylphenidate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexmethylphenidate."
Clinical Note
moderateBretylium + Methylphenidate
"Bretylium may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateCyamemazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate."
Clinical Note
moderateSulpiride + Methylphenidate
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
Immediate-release: 2–3 hours; Extended-release: 3–4 hours (drug), 6–8 hours (beaded forms). Context: Short half-life necessitates multiple daily dosing; sustained-release formulations prolong duration.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal: 90% (mostly as metabolites, primarily ritalinic acid), Fecal: <2%, Unchanged drug in urine: ~1%
Category C
Category A/B
CNS Stimulant
CNS Stimulant
"The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate."